Aspen Neuroscience lands $141M IPO, while Bambusa secures $169M
A Parkinson's cell therapy biotech and an I&I startup from former BioNTech leaders will join the public markets on Friday, extending a sizzling IPO streak for drug developers. Aspen Neuroscience will collect ...
Aspen Neuroscience, a clinical-stage biotech focused on Parkinson's disease, priced its IPO at $15 per share on Nasdaq, according to a company press release. The biotech plans to sell 9.375 million shares, projecting gross proceeds of around $140.6 million before fees. Aspen has given underwriters the option to buy up to an additional 1.406 million shares at the public offering price within 30 days.
The shares are slated to begin trading on the Nasdaq Global Select Market on October 30, 2026, with the offering expected to close on November 2, 2026, pending customary closing conditions. Aspen Neuroscience is led by Leerink Partners, Piper Sandler, Stifel, UBS Investment Bank, and Oppenheimer & Co. as joint bookrunners for the IPO.
The company's lead product, sasineprocel, is an investigational autologous iPSC-based cell therapy being tested as a single-dose treatment for Parkinson's disease.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Aspen Neuroscience prices IPO at $15 per share on Nasdaq investing.com
